A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B

Journal of Hepatology

Volumn 32, Issue 2, 2000, Pages 317-324

  Carreño, Vicente ^a,k   Zeuzem, Stefan ^b   Hopf, Uwe ^c   Marcellin, Patrick ^d   Cooksley, W Graham E ^e   Fevery, Johan ^f   Diago, Moisés ^g   Reddy, Rajender ^h   Peters, Marion ⁱ   Rittweger, Karen ^j   Rakhit, Ashok ^j   Pardo, Margarita ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Universitätklinik   (Germany)

^d BEAUJON HOSPITAL   (France)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HOFFMANN LA ROCHE INC   (United States)

^k HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

more..

Author keywords

Chronic hepatitis B; Hepatitis B virus e antibody; Hepatitis B virus e antigen; IL 12 pharmacodynamics; IL 12 pharmacokinetics; Interleukin (IL) 12 therapeutic use

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; NEOPTERIN; RECOMBINANT INTERLEUKIN 12;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SKIN TOXICITY; VERTIGO;

EID: 0033951496     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80078-1     Document Type: Article

References (38)

1. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
2. Perrillo RP, Mason AL. Therapy for hepatitis B virus infection. Gastroenterol Clin North Am. 23:1994;581-601.
3. Carreño V, Castillo I, Molina J, Porres JC, Bartolomé J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol. 15:1992;102-106.
4. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J, et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol. 88:1993;1887-1892.
5. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 119:1993;312-323.
6. Thomas HC, Lok ASF, Carreño V, Farrell G, Tanno H, Perez V, et al. Comparative study of three doses of interferon alfa-2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat. 1:1994;139-148.
7. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 334:1996;1422-1427.
8. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 113:1997;1660-1667.
9. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology. 10:1989;198-202.
10. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology. 15:1992;584-589.
11. López-Alcorocho JM, Bartolomé J, Cotonat T, Carreño V. Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy. J Viral Hepat. 4:((suppl. 1)):1997;27-32.
12. Colacino JM, Staschke KA. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res. 50:1998;259-322.
13. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 27:1998;1711-1716.
14. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 13:1995;29-60.
15. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 2:1996;1104-1108.
16. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest. 97:1996;1655-1665.
17. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 84:1994;4008-4027.
18. Hendrzak JA, Brunda MJ. Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab Invest. 72:1995;619-637.
19. Gately MK, Mulqueen MJ. Interleukin-12: potential clinical applications in the treatment and prevention of infectious diseases. Drugs. 52:((suppl. 2)):1996;18-26.
20. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 71:1997;3236-3243.
21. Desmet VJ, Gerber MA, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
22. Kuhns MC, McNamara AL, Cabal CM, Decker RH, Thiers V, Brechot C, et al. A new assay for quantitative detection of hepatitis B viral DNA in human serum. Zuckerman AJ. Viral Hepatitis and Liver Disease. 1988;258-262 Alan R. Liss Inc, New York.
23. Chizzonite R, Truitt T, Podlaski FJ, Wolitzky AG, Quinn PM, Nunes P, et al. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J Immunol. 147:1991;1548-1556.
24. Jaeckel E, Manns MP. Experience with lamivudine against hepatitis B virus. Intervirology. 40:1997;322-336.
25. Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology. 40:1997;337-342.
26. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 3:1997;409-417.
27. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90:1997;2541-2548.
28. Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, Goldman SJ. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun. 204:1994;1150-1157.
29. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res. 4:1998;75-85.
30. Quiroga JA, Martin J, Navas S, Carreño V. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis. 178:1998;247-251.
31. Zeuzem S, Hopf U, Carreño V, Diago M, Shiffman M, Grune S, et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology. 29:1999;1280-1287.
32. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 102:1998;968-975.
33. Bertoletti A, D'Elios MM, Boni C, De Carli M, Zignego AL, Durazzo M, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology. 112:1997;193-199.
34. Fernández M, Quiroga JA, Martín J, Cotonat T, Pardo M, Horisberger MA, et al. Impaired interferon induction of human MxA protein in chronic hepatitis B virus infection. J Med Virol. 51:1997;332-337.
35. Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, et al. Selective expansion of cytotoxic T lymphocytes with a CD4+ CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. J Immunol. 152:1994;3074-3087.
36. Milich DR, Wolf SF, Hughes JL, Jones JE. Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice. Proc Natl Acad Sci USA. 92:1995;6847-6851.
37. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol. 161:1998;4520-4529.
38. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest. 99:1997;3025-3033.